IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

Formulation and Evaluation of Transdermal Drug Delivery System

Galande Pallavi Manik, Sonwane Akhil Sudhakar, Sawant Satyajit Dilip
Aditya Pharmacy College, Beed

Abstract: *The study involves the Formulation and Evaluation of Transdermal Drug Delivery System. TDDS is a non-invasive technique that delivers drugs across the skin into systemic circulation, offering advantages such as avoidance of first-pass metabolism, controlled drug release, and improved patient compliance. A generalized transdermal formulation approach was adopted using suitable polymers, permeation enhancers, and solvents.*

The present study focuses on the formulation and evaluation of a Transdermal Drug Delivery System (TDDS) using Ibuprofen as a model drug. Transdermal delivery offers advantages such as avoidance of first-pass metabolism, sustained drug release, reduced dosing frequency, and improved patient compliance. Ibuprofen, a widely used non-steroidal anti-inflammatory drug (NSAID), was selected due to its suitable physicochemical properties such as moderate molecular weight (~206 Da), adequate lipophilicity (Log P ~3.5), and short biological half-life (~2 hours), making it an ideal candidate for transdermal administration.

The formulation was developed using polymers such as HPMC, PVP, and Carbopol along with permeation enhancers like DMSO and Propylene Glycol. Preformulation studies including solubility, partition coefficient, FTIR, and DSC confirmed compatibility and suitability of the drug. In-vitro diffusion studies demonstrated sustained drug release up to 24 hours, with optimized formulation (F4) showing maximum drug release and stability.

Keywords: Transdermal Drug Delivery System, Ibuprofen, Controlled Release, NSAIDs, Franz Diffusion Cell

I. INTRODUCTION

1.1 Rationale for Advanced Drug Delivery

Modern pharmacotherapy increasingly demands dosage forms that provide predictable plasma drug levels**,** improved safety, and enhanced patient adherence. Conventional oral delivery of analgesic drugs, especially non-steroidal anti-inflammatory drugs (NSAIDs), is often associated with gastrointestinal irritation, variable absorption, and frequent dosing requirements**.** These challenges have driven the development of novel delivery systems that can maintain therapeutic drug levels for extended durations.

Among these, transdermal drug delivery has emerged as a strategic alternative, offering controlled release and improved tolerability, particularly for chronic pain management.

1.2 Concept of Transdermal Drug Delivery

Transdermal drug delivery refers to the administration of therapeutic agents through intact skin to achieve systemic effects. Unlike topical formulations that act locally, transdermal systems are designed to deliver drugs across the skin barrier into systemic circulation.

This route integrates principles of diffusion kinetics, polymer science, and skin physiology, enabling sustained drug input over extended periods. The release rate can be tailored by modifying formulation variables such as polymer composition, enhancer concentration, and drug loading.

DOI: 10.48175/IJARSCT-35704

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

1.3 Biopharmaceutical Basis of Skin Permeation

The skin acts as a highly selective barrier due to the presence of the stratum corneum, which is composed of keratin-filled corneocytes embedded in a lipid matrix. This structure is often described as a "brick and mortar model", where:

- Corneocytes = bricks
- Lipid matrix = mortar

Drug permeation across the skin is governed by Fick's law of diffusion, where the flux depends on:

- Concentration gradient
- Diffusion coefficient
- Thickness of membrane



Fig. 1: Stratum Corneum (Skin Barrier)

Lipophilic drugs tend to diffuse through lipid domains, while hydrophilic drugs face resistance, making permeability a critical formulation challenge.

1.4 Need for Transdermal Delivery of NSAIDs

NSAIDs are widely used for the treatment of pain and inflammation but are associated with significant adverse effects when administered orally, such as:

- Gastric irritation and ulceration
- Hepatic metabolism (first-pass effect)
- Fluctuating plasma levels

Transdermal delivery offers a solution by:

- Bypassing gastrointestinal exposure
- Avoiding hepatic first-pass metabolism
- Providing localized as well as systemic effects
- Reducing dosing frequency

Thus, transdermal systems are particularly suitable for NSAIDs used in chronic conditions like arthritis and musculoskeletal pain.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 10, May 2026 Impact Factor: 8.2

1.5 Scientific Basis for Drug Selection: Ibuprofen

Ibuprofen is a propionic acid derivative belonging to the NSAID class and is extensively used for its analgesic, anti-inflammatory, and antipyretic properties.

Key Properties Supporting Transdermal Use:



Fig. 2: Chemical Formula of Ibuprofen

- **Molecular weight (~206 Da):** Suitable for skin permeation
- Partition coefficient (Log P ~3.5): Indicates balanced lipophilicity
- **Short half-life (~2 hours):** Requires sustained delivery
- **Dose flexibility:** Allows controlled release formulation
- **Therapeutic relevance:** Widely used in chronic pain conditions

These attributes make Ibuprofen an ideal candidate for developing a controlled transdermal system.

1.6 Role of Formulation Design in TDDS

The success of a transdermal system depends largely on formulation design. Key components include:

1.6.1 Polymeric Matrix System

The polymeric matrix forms the structural backbone of the transdermal system. It is responsible for:

- Drug incorporation and uniform distribution
- Control of drug release rate
- Mechanical strength and integrity of the formulation

Types of Polymers Used

- **Hydrophilic polymers:** HPMC (Hydroxypropyl Methylcellulose), PVP (Polyvinylpyrrolidone)
- **Gelling agents:** Carbopol

Functional Roles

1. Drug Release Control

   The polymer network governs how the drug diffuses from the formulation.

   o Hydrophilic polymers swell in the presence of water → form a gel layer o This gel layer acts as a **diffusion barrier**, slowing drug release

2. Matrix Formation

   Polymers create a **three-dimensional network** that traps drug molecules and releases them gradually.

3. Viscosity and Consistency

   Carbopol increases viscosity, ensuring:

   o Proper application on skin o Prevention of runoff o Better residence time

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 10, May 2026 Impact Factor: 8.2

4. Film-Forming Ability

Some polymers form thin films after application, improving contact with skin and enhancing drug absorption.

Polymer Combination Effect

- HPMC (controlled release) + PVP (enhanced solubility)

→ Provides balanced release profile

→ Prevents burst release

→ Improves uniformity

1.6.2 Permeation Enhancers

Permeation enhancers are crucial in TDDS because the stratum corneum acts as the primary barrier to drug penetration.

Functions

- Increase drug permeability through skin
- Reduce resistance of stratum corneum
- Enhance drug flux into systemic circulation

Common Enhancers Used

- Dimethyl Sulfoxide (DMSO)
- Propylene Glycol (PG)

Mechanisms of Action

1. Lipid Disruption

Enhancers disturb the ordered lipid structure of the stratum corneum, creating pathways for drug diffusion.

2. **Protein Interaction**

They interact with keratin in skin cells, increasing drug mobility.

3. **Improved Drug Solubility**

Enhancers increase the solubility of Ibuprofen in the skin layers.

4. Increased Partitioning

Facilitate transfer of drug from formulation → skin → systemic circulation

1.7 Permeation Enhancement Strategies

Due to the strong barrier function of the skin, permeation enhancers are essential for improving drug flux.

Mechanisms of Enhancers:

- Disruption of lipid bilayer
- Increased drug solubility
- Improved partitioning into skin Common enhancers used:
- Dimethyl Sulfoxide (DMSO)
- Propylene Glycol

These agents temporarily alter the barrier without causing permanent damage.

1.8 Controlled Release and Drug Kinetics

Transdermal systems are designed to provide controlled and sustained drug release, which helps maintain consistent plasma drug levels.

Drug release from TDDS typically follows:

- Diffusion-controlled mechanisms
- Matrix-based release systems

Mathematical models such as:

- Higuchi model
- Korsmeyer-Peppas model

Are used to describe release behavior and mechanism.

1.9 Challenges in Transdermal Drug Delivery

Despite its advantages, TDDS faces several challenges:

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 10, May 2026 Impact Factor: 8.2

- Limited permeability of many drugs
- Variability in skin properties among individuals
- Risk of irritation or sensitization
- Stability issues under varying environmental conditions

Addressing these challenges requires careful selection of drug, polymers, and enhancers.

1.10 Scope of the Present Study

The present study focuses on the development of a polymer-based transdermal drug delivery system of Ibuprofen with the aim of achieving:

- Sustained drug release over 24 hours
- Enhanced skin permeation using suitable enhancers
- Improved patient compliance
- Reduction of gastrointestinal side effects

The study integrates preformulation analysis, formulation design, evaluation, and stability assessment to develop an optimized transdermal system.

II. LITERATURE REVIEW

2.1 Introduction

Transdermal drug delivery systems (TDDS) have evolved significantly over the past few decades as an alternative to conventional dosage forms. Extensive research has been conducted to improve drug permeation through the skin, optimize formulation design, and enhance therapeutic efficacy. In the case of Ibuprofen, numerous studies have focused on overcoming its limitations such as poor aqueous solubility and moderate skin permeability, making it a challenging yet promising candidate for transdermal delivery..

2.2 Skin Barrier and Drug Permeation Studies

The skin, particularly the **stratum corneum**, acts as the primary barrier to drug permeation.

- The “brick and mortar” model explains the barrier function
- Lipid bilayers restrict hydrophilic drug penetration
- Diffusion is governed by Fick’s law

Research indicates that drug permeability depends on molecular weight, lipophilicity, and solubility Studies have shown that NSAIDs, including ibuprofen, possess favorable permeability characteristics but still require enhancement strategies for optimal delivery

- **Blank et al. (1984)** described the stratum corneum as the principal barrier to drug permeation due to its highly organized lipid structure.

2.3 Mechanism of Transdermal Drug Permeation

Drug permeation across the skin follows passive diffusion, governed by concentration gradient.

Pathways:

- Transcellular
- Intercellular
- Appendageal

The permeation process is described by **Fick’s Law of Diffusion**, where the rate depends on drug concentration, diffusion coefficient, and membrane thickness.

- **Fick (1855)** established the law of diffusion, which explains the rate of drug permeation across membranes.

2.4 Physicochemical Considerations of Ibuprofen

Ibuprofen exhibits properties that influence its transdermal delivery:

- Molecular weight: ~206 Da
- Log P: ~2.5–4.0
- Poor water solubility (~0.08 g/L)

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

- Moderate lipophilicity

These characteristics make ibuprofen partially suitable for transdermal delivery but require enhancement techniques to improve flux

Baker and Heller (1988) categorized TDDS into matrix and reservoir systems based on drug release mechanisms.

2.5 Role of Polymers in TDDS Polymers play a critical role in:

- Controlling drug release
- Providing structural integrity
- Enhancing stability Common Polymers:
- HPMC
- PVP
- Carbopol

Hydrophilic polymers promote faster drug release, while hydrophobic polymers provide sustained release.

Williams and Barry (2004) described permeation enhancers as agents that temporarily reduce the barrier resistance of the skin.

Barry (1987) reported that DMSO disrupts lipid structure and enhances drug penetration.

Guy and Hadgraft (2003) emphasized the role of enhancers in improving drug flux across the skin.

2.6 Permeation Enhancers

Permeation enhancers improve drug penetration by:

- Disrupting lipid structure of stratum corneum
- Increasing drug solubility
- Enhancing partitioning into skin

Examples:

- DMSO
- Propylene glycol
- Oleic acid

2.7 Factors Affecting Transdermal Drug Delivery

Drug-related factors

- Molecular weight
- Lipophilicity
- Solubility

Formulation-related factors

- Polymer type
- Enhancer concentration
- Vehicle composition

Physiological factors

- Skin hydration
- Age
- Skin thickness

2.8 Previous Research Studies on TDDS

Several studies have demonstrated the effectiveness of TDDS:

- Studies on NSAIDs showed improved permeation and reduced gastrointestinal side effects
- Polymer combinations like HPMC and PVP provided controlled drug release
- Use of enhancers significantly increased drug flux across the skin

Jain and Tiwary (2007) formulated transdermal systems and reported improved drug release and patient compliance.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

2.9 Studies on Ibuprofen in TDDS

Ibuprofen has been widely studied for transdermal delivery due to:

- Suitable molecular weight
- Lipophilicity
- Anti-inflammatory activity

Research findings:

- Enhanced permeation using DMSO
- Sustained release using polymeric systems
- Improved bioavailability compared to oral route

III. AIM AND OBJECTIVES

3.1 Aim

To formulate and evaluate a Transdermal Drug Delivery System (TDDS) using Ibuprofen as a model drug, with the objective of achieving controlled drug release, enhanced skin permeation, and improved therapeutic efficacy.

3.2 Objectives

1. To study the fundamental principles and mechanisms involved in transdermal drug delivery systems
2. To select a suitable model drug (Ibuprofen) based on its physicochemical and pharmacological properties
3. To carry out preformulation studies including solubility, partition coefficient, and drug–excipient compatibility
4. To select appropriate polymers and excipients for the formulation of TDDS
5. To develop a general transdermal formulation using suitable methods
6. To incorporate permeation enhancers to improve drug penetration through the skin.
7. To evaluate the prepared formulation for physicochemical parameters such as appearance, pH, viscosity, and homogeneity.
8. To determine drug content uniformity of the formulation.
9. To perform in-vitro drug release studies using Franz diffusion cell.
10. To study drug permeation behavior across a suitable membrane.
11. To analyze the drug release kinetics using mathematical models.
12. To conduct stability studies as per ICH guidelines.

IV. MATERIALS AND METHODS

4.1 Materials

4.1.1 Drug

Ibuprofen (Model drug for transdermal delivery)

4.1.2 Polymers

- Hydroxypropyl Methylcellulose (HPMC)
- Polyvinylpyrrolidone (PVP K30)
- Carbopol 934

4.1.3 Permeation Enhancers

- Dimethyl Sulfoxide (DMSO)
- Propylene Glycol (PG)

4.1.4 Solvents and Other Chemicals

- Ethanol (drug solvent)
- Methanol (analytical solvent)

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

- Distilled water (polymer dispersion)
- Triethanolamine (neutralizing agent for Carbopol)
- Phosphate buffer pH 7.4 (diffusion medium)

4.1.5 Biological Membrane

- Egg membrane
- Cellophane membrane (for in-vitro diffusion)

4.1.6 List of Materials (Table)

Material	Category	Function
Ibuprofen	Drug	Analgesic
HPMC	Polymer	Controlled release
PVP	Polymer	Solubility enhancer
Carbopol	Polymer	Gel formation
DMSO	Enhancer	Increases permeability
Propylene glycol	Enhancer	Improves diffusion
Ethanol	Solvent	Drug dissolution

4.2 Instruments and Equipment

Instrument	Use
Digital Balance	Accurate weighing
Magnetic Stirrer	Mixing
pH Meter	pH measurement
UV Spectrophotometer	Drug analysis
Franz Diffusion Cell	In-vitro permeation
Viscometer	Viscosity measurement

4.3 Methodology Overview The study involved:

1. Preformulation studies
2. Formulation of TDDS
3. Evaluation of prepared system
4. Drug release and permeation studies

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

4.4 Preparation of Transdermal Drug Delivery System

Method: Solvent Casting Technique

Step-by-Step Procedure

Step 1: Drug Solubilization

- Accurately weighed quantity of Ibuprofen was taken
- Dissolved in ethanol under continuous stirring

Step 2: Polymer Hydration

- Required quantities of HPMC and PVP were dispersed in distilled water
- Allowed to hydrate for 1–2 hours to form a uniform solution

Step 3: Preparation of Polymer Matrix

- Carbopol was dispersed separately in water
- Neutralized using triethanolamine to form gel

Step 4: Incorporation of Drug

- Drug solution was slowly added to polymer mixture
- Continuous stirring ensured uniform dispersion

Step 5: Addition of Permeation Enhancers

- DMSO and Propylene Glycol added
- Mixed thoroughly to ensure uniform distribution

Step 6: Homogenization

- Mixture stirred using magnetic stirrer
- Air bubbles removed to obtain smooth formulation

Step 7: Casting and Drying

- Prepared mixture poured into molds or petri plates
- Allowed to dry at room temperature

Step 8: Storage

- Final formulation stored in airtight containers

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

Flowchart of TDDS Preparation



Fig. 3: Flowchart of TDDS Preparation

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

4.5 Formulation Design

Formulation Table

Formulation	HPMC (mg)	PVP (mg)	Carbopol (%)	DMSO (%)	PG (%)	Drug (mg)
F1	200	200	1%	—	—	100
F2	300	100	1%	5%	—	100
F3	100	300	1%	—	5%	100
F4	200	200	1%	5%	5%	100

4.6 Preformulation Studies

- Organoleptic Properties
- Solubility Study
- Partition Coefficient
- FTIR Study
- DSC Study

4.7 Evaluation of TDDS

4.7.1 Physical Evaluation

- Appearance
- Homogeneity
- pH

4.7.2 Viscosity Measurement

- Measured using Brookfield viscometer

4.7.3 Spreadability

- Evaluated using glass slide method

4.7.4 Drug Content Uniformity

- Sample dissolved in solvent
- Analyzed using UV spectrophotometer

4.7.5 In-vitro Diffusion Study Procedure:

- Franz diffusion cell used
- Membrane mounted between compartments
- Receptor medium: phosphate buffer pH 7.4
- Samples withdrawn at intervals

4.7.6 Drug Release Kinetics

- Zero-order First-order
- Higuchi model
- Korsmeyer-Peppas model

4.7.7 Skin Irritation Study

- Applied on animal skin
- Observed for redness or irritation

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

V. PREFORMULATION STUDIES

5.1 Introduction

Preformulation studies are the preliminary investigations carried out to evaluate the physicochemical and biopharmaceutical properties of a drug substance before formulation development. These studies provide essential information regarding the compatibility, stability, solubility, and permeability characteristics of the drug, which directly influence formulation performance.

In the present study, Ibuprofen was evaluated for its suitability in transdermal drug delivery. Since the success of TDDS depends largely on the drug's ability to permeate through the skin barrier, properties such as molecular weight, lipophilicity, partition coefficient, and compatibility with excipients were carefully studied.

The preformulation parameters investigated included:

- Organoleptic properties
- Solubility analysis
- Partition coefficient
- Melting point determination
- FTIR compatibility studies
- Differential Scanning Calorimetry (DSC)
- Moisture content analysis
- Drug content estimation

5.2 Organoleptic Properties

Property	Observation	Inference
Color	White	Pure sample
Appearance	Crystalline powder	Acceptable
Odor	Characteristic	Typical
Taste	Slightly bitter	NSAID characteristic

5.3 Solubility Studies

Objective

To determine solubility of Ibuprofen in different solvents.

Solvent	Solubility	Observation
Distilled Water	Slightly soluble	Poor aqueous solubility
Methanol	Freely soluble	Suitable solvent
Ethanol	Freely soluble	Preferred solvent
Chloroform	Soluble	Good solubility

Conclusion

Ibuprofen shows better solubility in organic solvents, supporting its use in transdermal formulations.

5.4 Partition Coefficient (Log P)

Method

Shake flask method using:

- n-octanol
- Phosphate buffer (pH 7.4)

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

Result

- Log P ≈ **3.1**

Interpretation

Indicates good lipophilicity

Suitable for transdermal delivery

5.5 FTIR Spectral Analysis

Objective

To check drug–excipient compatibility.

Observed Peaks

Functional Group	Standard (cm^{-1})	Observed (cm^{-1})
O–H Stretch	~3300	3295
C=O Stretch	~1700	1698
Aromatic C=C	~1600	1602

Conclusion

No significant shift observed → No interaction between drug and excipients

5.6 Differential Scanning Calorimetry (DSC)

Observation

- Sharp endothermic peak at ~94–97°C (melting point of Ibuprofen)

Conclusion

- No change in peak → Drug remains stable
- Confirms compatibility

5.7 Moisture Content and Uptake

Formulation	Moisture Content (%)	Moisture Uptake (%)
F1	3.1	4.5
F2	2.8	4.2
F3	3.0	4.6
F4	2.6	4.0

Conclusion

- Low moisture content ensures stability
- Moderate uptake indicates good environmental resistance

5.8 Drug Content Uniformity

Formulation	Drug Content (%)
F1	97.2
F2	98.5

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

F3	99.1
F4	98.7

Conclusion

All formulations fall within acceptable range (95–105%)

5.9 Thickness / Consistency

Formulation	Observation
F1	Smooth
F2	Slightly viscous
F3	Uniform
F4	Optimal consistency

5.10 pH Measurement

Formulation	pH
F1	6.5
F2	6.6
F3	6.7
F4	6.8

Conclusion pH is within skin-compatible range → **No irritation expected**

VI. FORMULATION DEVELOPMENT

Formulation development is a critical phase in the design of an effective Transdermal Drug Delivery System (TDDS). It involves the selection and optimization of polymers, permeation enhancers, solvents, and processing methods to achieve sustained drug release, adequate skin permeation, and formulation stability.

In the present study, Ibuprofen was formulated into a polymer-based transdermal system using different combinations of hydrophilic polymers and permeation enhancers. The formulation was designed to improve therapeutic efficacy, prolong drug release, and reduce gastrointestinal side effects associated with oral administration.

The solvent casting technique was selected because of:

- Simplicity of preparation
- Uniform drug distribution
- Cost-effectiveness
- Reproducibility

6.1 Rationale for Drug Selection

Ibuprofen was selected for transdermal delivery due to its favorable physicochemical and pharmacological properties.

Advantages of Ibuprofen for TDDS

- Low molecular weight (~206 Da)
- Moderate lipophilicity (Log P ~3.5) □ Short biological half-life (~2 hours)
- Potent analgesic and anti-inflammatory activity
- Reduced gastric irritation through transdermal route

These properties make Ibuprofen a suitable candidate for sustained transdermal therapy.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

6.2 Selection of Excipients

Component	Role	Justification
HPMC	Polymer	Controls drug release
PVP	Polymer	Enhances solubility
Carbopol	Gelling agent	Provides viscosity
DMSO	Enhancer	Improves permeation
Propylene Glycol	Enhancer	Increases diffusion
Ethanol	Solvent	Dissolves drug

6.3 Formulation Design

Different formulations (F1–F4) were prepared by varying polymer ratios and enhancer concentrations.

Formulation Table

Formulation	HPMC (mg)	PVP (mg)	Carbopol (%)	DMSO (%)	PG (%)	Drug (mg)
F1	200	200	1%	—	—	100
F2	300	100	1%	5%	—	100
F3	100	300	1%	—	5%	100
F4	200	200	1%	5%	5%	100

6.4 Method of Preparation

General Procedure

1. **Polymer Preparation**
   - HPMC and PVP were weighed accurately
   - Dissolved in distilled water
   - Allowed to hydrate for 1–2 hours
2. **Drug Solution Preparation**
   - Ibuprofen dissolved in ethanol
3. **Mixing**
   - Drug solution added to polymer solution
   - Stirred continuously
4. **Addition of Enhancers**
   - DMSO and Propylene Glycol added
   - Mixed uniformly
5. **Gel Formation (if Carbopol used)**
   - Carbopol dispersed and neutralized using triethanolamine
6. **Homogenization**

DOI: 10.48175/IJARSCT-35704

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

Stirred using magnetic stirrer to obtain uniform system

7. **Storage**
   - o Stored in airtight container

Flowchart of Formulation Process



Fig. 4: Flowchart of Formulation Process

6.5 Optimization Strategy

Initial trials were conducted to optimize:

- Polymer ratio
- Enhancer concentration
- Viscosity and consistency

Observations

Trial	Observation
Low polymer	Poor consistency
High polymer	Thick formulation
Balanced ratio	Smooth and uniform

Optimized formulation: F4

6.6 Problems Encountered and Solutions

Problem	Cause	Solution

DOI: 10.48175/IJARSCT-35704

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

Phase separation	Improper mixing	Increase stirring time
Low viscosity	Low polymer concentration	Increase Carbopol
Poor drug release	Low enhancer	Add DMSO/PG
Stickiness	Excess polymer	Optimize ratio

6.7 Evaluation Summary (Preliminary)

Formulation	Consistency	Homogeneity	Spreadability
F1	Moderate	Good	Moderate
F2	Thick	Good	Good
F3	Thin	Good	High
F4	Optimal	Excellent	Excellent

VII. EVALUATION OF TRANSDERMAL DRUG DELIVERY SYSTEM

7.1 Introduction

Evaluation of TDDS is essential to ensure the formulation meets required standards for quality, stability, drug release, and safety. Various physicochemical and in-vitro parameters were assessed to determine the performance of the prepared formulations (F1–F4).

7.2 Physicochemical Evaluation

7.2.1 Appearance and Homogeneity

All formulations were visually inspected for:

Color

Uniformity

Presence of lumps

Formulation	Appearance	Homogeneity
F1	Clear	Good
F2	Slightly viscous	Good
F3	Smooth	Good
F4	Transparent	Excellent

Inference: All formulations were uniform and acceptable.

7.2.2 pH Measurement

- Measured using digital pH meter

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

Formulation	pH
F1	6.5
F2	6.6
F3	6.7
F4	6.8

Inference: Within skin-compatible range (5.5–7.0)

7.2.3 Viscosity

- Measured using Brookfield viscometer

Formulation	Viscosity (cps)
F1	3500
F2	4200
F3	3000
F4	4500

Inference: F4 shows optimal viscosity

7.2.4 Spreadability

- Measured using glass slide method

Formulation	Spreadability
F1	Moderate
F2	Good
F3	Very good
F4	Excellent

Inference: Good spreadability ensures ease of application

7.3 Drug Content Uniformity

- Analyzed using UV spectrophotometer

Formulation	Drug Content (%)
F1	97.5
F2	98.2

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

F3	96.8
F4	99.1

Inference: All within acceptable range (95–105%)

7.4 In-vitro Drug Release Study

- Performed using Franz diffusion cell
- Medium: Phosphate buffer pH 7.4

Cumulative Drug Release (%)

Time (hr)	**F1**	**F2**	**F3**	**F4**
1	12.3	13.5	11.8	14.2
2	25.6	28.1	23.4	30.5
4	45.2	48.6	41.5	52.3
6	60.5	65.2	58.0	70.8
8	75.8	80.4	72.6	85.1
12	88.6	91.2	85.3	94.5
24	92.4	95.3	90.1	97.8

Inference: F4 shows highest drug release

7.5 Drug Release Kinetics Drug release data fitted into models:

Model	**F1**	**F2**	**F3**	**F4**
Zero Order (R^2)	0.960	0.965	0.958	0.972
First Order (R^2)	0.880	0.890	0.875	0.900
Higuchi (R^2)	0.978	0.982	0.975	0.986
Korsmeyer-Peppas (R^2)	0.990	0.993	0.989	0.996

Inference:
Best fit = Korsmeyer-Peppas model Mechanism = Fickian diffusion

7.6 Skin Irritation Study

- Applied on skin surface

DOI: 10.48175/IJARSCT-35704

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

- Observed for redness, swelling

Parameter	Observation
Irritation	None
Redness	Absent

Inference: Safe for transdermal application

7.7 Summary of Evaluation

Parameter	Best Formulation
Viscosity	F4
Spreadability	F4
Drug Content	F4
Drug Release	F4

Optimized formulation: F4

VIII. STABILITY STUDIES

8.1 Introduction

Stability studies are essential to determine the shelf life, safety, and efficacy of pharmaceutical formulations. They ensure that the formulation maintains its physical, chemical, and therapeutic properties over time under different environmental conditions.

For Transdermal Drug Delivery Systems (TDDS), stability studies are particularly important because changes in temperature and humidity can affect:

- Drug content
- Consistency/viscosity
- Drug release behavior
- Appearance

8.2 Objective

- To evaluate the stability of the optimized formulation (F4)
- To study the effect of temperature and humidity on formulation properties
- To ensure compliance with ICH guidelines

8.3 Storage Conditions (ICH Guidelines)

Condition	Temperature	Humidity	Duration
Accelerated	40°C ± 2°C	75% RH ± 5%	3 months
Room Temp	25°C ± 2°C	60% RH ± 5%	Optional

8.4 Methodology

- Optimized formulation (F4) was selected
- Stored in airtight containers Evaluated at intervals:

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

- 0 month
- 1 month
- 2 months
- 3 months

Parameters Evaluated

- Appearance
- pH
- Drug content
- Viscosity
- Drug release

8.5 Results

Table 8.1: Stability Data of Formulation F4

Parameter	Initial	1 Month	2 Months	3 Months
Appearance	Clear	No change	No change	No change
pH	6.8	6.7	6.8	6.8
Drug Content (%)	99.1	98.8	98.5	98.2
Viscosity (cps)	4500	4480	4450	4420
Drug Release (%) (8 hr)	85.1	84.8	84.5	84.2

8.6 Interpretation of Results

- **Appearance:** No discoloration or phase separation observed
- **pH:** Remained within acceptable skin range
- **Drug Content:** Slight decrease but within acceptable limits
- **Viscosity:** Minor decrease, indicating good stability
- **Drug Release:** No significant change

Inference: Formulation is stable under accelerated conditions

8.7 Graphical Representation



IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

Fig 5: Drug Content (%) vs. Time



Fig 6: Cumulative Drug Release (%) Over Time



Fig. 7: Moisture Content Trend over Storage Duration

IX. RESULTS AND DISCUSSION

9.1 Physical Evaluation

The observations, experimental findings, and interpretations from the development and evaluation of transdermal designed for pain management. The results have been systematically analyzed to assess the efficiency, stability, and therapeutic potential of the formulations. This chapter presents the experimental findings, data analysis, and interpretation obtained during the formulation and evaluation of the Transdermal Drug Delivery System (TDDS). The results are discussed in relation to formulation variables such as polymer ratio and permeation enhancers.

9.2 Preformulation Study Results

9.2.1 Organoleptic Properties

Ibuprofen was found to be a white, odorless crystalline powder, indicating suitability for formulation without affecting patient acceptability.

9.2.2 Solubility

Ibuprofen showed:

- Poor solubility in water

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

- Good solubility in ethanol and methanol

Discussion:

This confirms the need for organic solvents and permeation enhancers in TDDS.

9.2.3 Partition Coefficient

- Log P ≈ **3.1**

Discussion:

This value indicates ideal lipophilicity, making Ibuprofen suitable for transdermal delivery.

9.3 Physicochemical Evaluation 9.3.1

Appearance and Homogeneity All formulations were:

- Smooth
- Uniform
- Free from lumps

Discussion:

Indicates proper mixing and formulation stability.

9.3.2 pH

Formulation	pH
F1	6.5
F2	6.6
F3	6.7
F4	6.8

Discussion:

All values fall within skin-compatible range, reducing irritation risk.

9.3.3 Viscosity

Formulation	Viscosity (cps)
F1	3500
F2	4200
F3	3000
F4	4500

Discussion:

- Increase in polymer concentration → increase in viscosity
- F4 shows optimal consistency for application

9.3.4 Spreadability

Formulation	Spreadability
F1	Moderate
F2	Good

DOI: 10.48175/IJARSCT-35704

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

F3	Very Good
F4	Excellent

Discussion:

Higher spreadability improves ease of application and patient compliance

9.4 Drug Content Uniformity

Formulation	Drug Content (%)
F1	97.5
F2	98.2
F3	96.8
F4	99.1

Discussion:

Uniform drug distribution confirms successful formulation technique

9.5 In-vitro Drug Release Study

Cumulative Drug Release (%)

Time (hr)	F1	F2	F3	F4
1	12.3	13.5	11.8	14.2
4	45.2	48.6	41.5	52.3
8	75.8	80.4	72.6	85.1
12	88.6	91.2	85.3	94.5
24	92.4	95.3	90.1	97.8

Discussion:

- All formulations showed **sustained drug release**
- F4 exhibited maximum drug release (97.8%)
- Enhancers (DMSO + PG) improved permeation

9.6 Drug Release Kinetics

Model	F4 (R^2)
Zero Order	0.972
First Order	0.900
Higuchi	0.986
Korsmeyer-Peppas	0.996

Discussion:

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 10, May 2026 Impact Factor: 8.2

- Best fit = Korsmeyer-Peppas model
- Indicates Fickian diffusion mechanism
- Drug release controlled by diffusion through polymer matrix

9.7 Skin Irritation Study

- No redness, swelling, or irritation observed

Discussion:

Formulation is safe and suitable for transdermal use

9.8 Stability Study Results

Parameter	Observation
Appearance	No change
Drug Content	Slight decrease but acceptable
pH	Stable
Drug Release	No significant change

X. SUMMARY AND CONCLUSION

10.1 Summary

The present study was carried out to develop and evaluate a general Transdermal Drug Delivery System (TDDS) using Ibuprofen as a model drug.

The work was systematically performed in the following stages:

1. Preformulation Studies
   - Physicochemical properties such as solubility, partition coefficient, FTIR, and DSC were evaluated
   - Results confirmed that Ibuprofen is suitable for transdermal delivery
   - No drug–excipient interaction was observed
2. Formulation Development
   - TDDS formulations (F1–F4) were prepared using different polymer ratios
   - Permeation enhancers (DMSO and Propylene Glycol) were incorporated
   - The formulations were optimized based on consistency and uniformity
3. Evaluation of TDDS
   - All formulations showed acceptable:
     - Appearance
     - pH
     - Viscosity
     - Spreadability
   - Drug content ranged between 96–99%, indicating uniform distribution
   - In-vitro drug release studies showed sustained release up to 24 hours
4. Drug Release Kinetics
   - Best fit model: **Korsmeyer-Peppas**
   - Mechanism: **Fickian diffusion**
5. Stability Studies
   - Conducted under accelerated conditions (40°C / 75% RH)
   - No significant changes observed
   - Formulation remained stable

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 10, May 2026 Impact Factor: 8.2

10.2 Conclusion

The study successfully demonstrated that a general TDDS can be formulated effectively using suitable polymers and permeation enhancers.

Key conclusions:

- Ibuprofen is an ideal candidate for transdermal delivery
- TDDS provided controlled and sustained drug release
- Permeation enhancers significantly improved drug diffusion
- Optimized formulation (**F4**) showed best performance The developed system is:
  - Safe
  - Stable
  - Effective

Therefore, TDDS serves as a promising alternative to conventional oral drug delivery systems, improving therapeutic efficacy and patient compliance.

REFERENCES

1. Ibuprofen transdermal patch formulation and evaluation studies. *International Journal of Pharmaceutical Sciences Review and Research*. 2019;58(2):45–52.
2. Prausnitz MR, Langer R. Transdermal drug delivery. *Nature Biotechnology*. 2008;26(11):1261–1268.
3. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. *European Journal of Pharmaceutical Sciences*. 2001;14(2):101–114.
4. Jain S, Tiwary AK. Formulation and evaluation of transdermal drug delivery systems. *AAPS PharmSciTech*. 2007;8(4):E1–E9.
5. Williams AC, Barry BW. Penetration enhancers. *Advanced Drug Delivery Reviews*. 2012;64:128–137.
6. Guy RH, Hadgraft J. Transdermal drug delivery systems. *Drug Development and Industrial Pharmacy*. 2003;29(1):1–10.
7. Chien YW. Novel drug delivery systems. 2nd ed. New York: Marcel Dekker; 2005.
8. Hadgraft J. Skin, the final frontier. *International Journal of Pharmaceutics*. 2001;224(1– 2):1–18.
9. Potts RO, Guy RH. Predicting skin permeability. *Pharmaceutical Research*. 1992;9(5):663–669.
10. Benson HAE. Transdermal drug delivery: penetration enhancement techniques. *Current Drug Delivery*. 2005;2(1):23–33.
11. Vyas SP, Khar RK. Controlled drug delivery concepts and advances. CBS Publishers; 2012.
12. Patel RP, Baria AH. Formulation and evaluation of transdermal patches of NSAIDs. *International Journal of Drug Delivery*. 2011;3(2):287–295.
13. Rani S, Dahiya M. Formulation and evaluation of Ibuprofen transdermal patches. *International Journal of Pharmacy and Pharmaceutical Sciences*. 2012;4(3):242–246.
14. Tanner T, Marks R. Delivering drugs by the transdermal route. *Skin Research and Technology*. 2008;14(3):249–260.
15. Aulton ME. Pharmaceutics: The science of dosage form design. 4th ed. Churchill Livingstone; 2013.
16. Brahmankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics. Vallabh Prakashan; 2015.
17. Allen LV, Popovich NG, Ansel HC. Pharmaceutical dosage forms and drug delivery systems. Lippincott Williams & Wilkins; 2014.
18. Lachman L, Lieberman HA, Kanig JL. Theory and practice of industrial pharmacy. CBS Publishers; 2013.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 10, May 2026
Impact Factor: 8.2

19. Banker GS, Rhodes CT. Modern pharmaceutics. Marcel Dekker; 2002.
20. Keleb EI, Sharma RK, Mosa EB, Aljahwi AZ. Transdermal drug delivery system design and evaluation. *International Journal of Advances in Pharmaceutical Sciences*. 2010;1(3):201–211.
21. Aqil M, Ali A. Monolithic matrix type transdermal drug delivery systems. *Drug Development and Industrial Pharmacy*. 2003;29(1):89–97.
22. Kulkarni RV, Mutalik S, Hiremath D. Effect of permeation enhancers on transdermal delivery of NSAIDs. *Indian Journal of Pharmaceutical Sciences*. 2011;73(2):154–161.
23. Mutalik S, Udupa N. Formulation development and evaluation of membrane controlled transdermal systems. *Indian Drugs*. 2004;41(10):593–598.
24. Moghadam SH, Saliaj E, Wettig SD, Dong C, Ivanova MV, Haddleton DM. Enhanced transdermal delivery of Ibuprofen. *Molecular Pharmaceutics*. 2013;10(2):484–495.
25. Sintov AC, Botner S. Transdermal delivery of Ibuprofen using microemulsions. *International Journal of Pharmaceutics*. 2006;311(1–2):55–62.
26. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to transdermal osmotic gradients. *Biochimica et Biophysica Acta*. 1992;1104(1):226–232.
27. Barry BW. Breaching the skin's barrier to drugs. *Nature Biotechnology*. 2004;22(2):165– 167.
28. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming skin barrier function. *Pharmaceutical Science and Technology Today*. 2000;3(9):318–326.
29. Escobar-Chávez JJ, Merino V, López-Cervantes M. The use of sonophoresis in transdermal drug delivery. *Journal of Pharmacy and Pharmaceutical Sciences*. 2009;12(1):88–115.
30. Prausnitz MR. Microneedles for transdermal drug delivery. *Advanced Drug Delivery Reviews*. 2004;56(5):581–587.
31. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems. *Drug Delivery*. 2006;13(3):175–187.
32. Kanikkannan N. Technologies to improve transdermal drug delivery. *BioDrugs*. 2002;16(5):339–347.
33. Pathan IB, Setty CM. Chemical penetration enhancers for transdermal drug delivery systems. *Tropical Journal of Pharmaceutical Research*. 2009;8(2):173–179.
34. Kumar R, Philip A. Modified transdermal technologies: breaking the barriers of drug permeation. *International Journal of Pharmaceutical Sciences*. 2007;69(5):633–644.
35. Singh MC, Naik AS, Sawant SD. Transdermal drug delivery systems with major emphasis on transdermal patches. *Journal of Pharmacy Research*. 2010;3(10):2537–2543.
36. Gupta R, Mukherjee B. Development and in vitro evaluation of diltiazem hydrochloride transdermal patches. *International Journal of Pharmaceutical Sciences*. 2003;65(4):345– 348.
37. Ubaidulla U, Reddy MV, Ruckmani K. Transdermal therapeutic system of carvedilol. *Current Drug Delivery*. 2007;4(1):69–76.
38. Saroha K, Yadav B, Sharma B. Transdermal patches: a successful tool in transdermal drug delivery system. *Pelagia Research Library*. 2011;2(5):17–29.
39. Gannu R, Palem CR, Yamsani VV. Transdermal drug delivery systems: an overview. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*. 2010;1(4):104– 118.
40. Qureshi SA, McGilveray IJ. Typical profiles of drug dissolution and release. *Drug Information Journal*. 1998;32(4):963–974.